Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when INCY files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsIncyte closes $1.25B Vega acquisition, adds Phase 3 bleeding-disorder drug VGA039
Filed July 6, 2026 · Period ending July 6, 2026 · ~1 min read
Key Changes
-
high
Incyte paid $1.25B upfront for Vega Therapeutics, with up to $750M in sales milestones. The company will record the transaction as a one-time R&D expense in Q3 and full year 2026 results.
Item 8.01 — Other Events verify on EDGAR → -
high
The acquisition adds VGA039, a Phase 3 monoclonal antibody for von Willebrand disease with FDA Breakthrough Therapy, Fast Track, orphan drug and rare pediatric disease designations.
Item 8.01 — Other Events verify on EDGAR → -
high
VGA039 is in the Phase 3 VIVID-6 study evaluating once-monthly subcutaneous prophylaxis for all types of VWD. Current treatments require frequent intravenous infusions.
Item 8.01 — Other Events verify on EDGAR → -
medium
Approximately 135,000 people in the United States have been diagnosed with von Willebrand disease, the most common inherited bleeding disorder.
Item 8.01 — Other Events verify on EDGAR →
Summary
Incyte has closed its acquisition of Vega Therapeutics for $1.25 billion upfront plus up to $750 million in sales-based milestones, adding VGA039 to its hematology portfolio. VGA039 is a Phase 3 monoclonal antibody targeting Protein S for von Willebrand disease, the most common inherited bleeding disorder affecting approximately 135,000 diagnosed Americans.
The drug has received multiple FDA designations including Breakthrough Therapy and Fast Track status, and is currently in the global Phase 3 VIVID-6 study. For investors, the acquisition represents a significant capital deployment that will hit earnings as a one-time R&D expense in Q3 and full-year 2026 results.
The strategic rationale centers on VGA039's potential as the first once-monthly subcutaneous prophylactic therapy for VWD patients, who currently require frequent intravenous infusions. The drug's Phase 3 status and regulatory designations suggest a relatively de-risked asset, though commercial success remains contingent on trial outcomes and eventual approval. The milestone structure ties a meaningful portion of the total consideration to future sales performance.
Section-by-Section Diff
Event · Item 8.01 — Other Events
Incyte completed its acquisition of Vega Therapeutics, a wholly owned subsidiary of Star Therapeutics LLC.
Added in current filing · verify on EDGAR →
On July 6, 2026, Incyte Corporation (the “Company”) issued a press release announcing it has completed its previously announced acquisition of Vega Therapeutics, Inc., a wholly owned subsidiary of Star Therapeutics LLC (“Vega Therapeutics”).
Incyte has closed its acquisition of Vega Therapeutics, Inc., which was a wholly owned subsidiary of Star Therapeutics LLC. The 8-K confirms the transaction is complete as of July 6, 2026, but does not disclose financial terms, strategic rationale, or integration plans.
Event · Exhibit 99.1
Added in current filing · view on EDGAR →
Incyte (Nasdaq:INCY) announced today it has completed its acquisition of Vega Therapeutics, Inc., a wholly owned subsidiary of Star Therapeutics LLC. The acquisition adds VGA039, a novel monoclonal antibody in Phase 3 development for von Willebrand disease (VWD), the most common inherited bleeding disorder, to Incyte’s hematology portfolio.
Incyte closed its acquisition of Vega Therapeutics, gaining VGA039, a Phase 3 monoclonal antibody for von Willebrand disease. VGA039 has received Breakthrough Therapy, Fast Track, orphan drug and rare pediatric disease designations from the FDA and is in the Phase 3 VIVID-6 study. The drug targets Protein S to improve hemostasis and could be the first once-monthly subcutaneous prophylactic therapy for VWD patients, who currently require frequent intravenous infusions.
Added in current filing · view on EDGAR →
VGA039 has advanced into the Phase 3 VIVID-6 study (NCT07115004), a global single arm cross-over study to investigate safety and efficacy of the subcutaneous administration of VGA039 as prophylaxis for bleeding in patients with every type of VWD, including those with a high disease burden.
VGA039 is currently in the Phase 3 VIVID-6 study, a global single-arm crossover trial evaluating subcutaneous VGA039 as prophylaxis for bleeding in all types of von Willebrand disease. The drug modulates Protein S to improve hemostasis and has potential application across multiple bleeding disorders. Approximately 135,000 people in the United States have been diagnosed with von Willebrand disease.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jul 7, 2026 · How we verify